AbbVie's SWOT analysis: biopharma giant navigates post-Humira landscape
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...
Why AbbVie Stock Popped While the Market Flopped on Monday
Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...
5 Must-See Stocks with Perfect Earnings Charts
These 5 companies have not missed on earnings in 5 years. That's an impressive feat with the pandemic hitting in 2020.
AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains
AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.
AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive
AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...
AbbVie A Top Socially Responsible Dividend Stock With 3.9% Yield
The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...
AbbVie price target raised to $227 from $220 at Piper Sandler
Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $227 from $220 and keeps an Overweight rating on ...
Goldman Sachs raises AbbVie stock price target to $208
Goldman Sachs updated its financial model for AbbVie (NYSE:ABBV), leading to an increase in the price target for the ...
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price ...